IMA901
- Generic Name
- IMA901
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
IMA901 is a vaccine consists of tumor-associated peptides (TUMAPs).
- Indication
Investigated for use/treatment in kidney cancer.
- Associated Conditions
- -
- Associated Therapies
- -
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 339
- Registration Number
- NCT01265901
- Locations
- 🇷🇴
Medisprof SRL, Cluj-Napoca, Romania
🇺🇸Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, D.C., District of Columbia, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath